MDxHealth « Terug naar discussie overzicht

quote:

De Troon Jan schreef op 6 juni 2018 22:55:

Je weet nooit las vandaag weer in de krant dat Philips epd solutions heeft overgenomen....voor 250 milj. En tuurlijk is hun omzet beter en veel hoger maar niet op dit gebied.... lees veel in de krant en Philips is en blijft Eindhoven.......

quote:

vreemd vermogen schreef op 7 juni 2018 10:50:

Vertel er dan ook even bij hoe Philips begonnen is.

quote:

Poelifinario schreef op 7 juni 2018 15:05:

Biocartis is ook een spin off van Philips.

Philips heeft het volgende recht op biocartisaandelen:

[1] The conversion option agreement allows Philips to convert certain royalty and other payments due to it up to a maximum of 10% of the then outstanding capital of the Company on a fully diluted post-money basis, but only if the Company has not yet made a lump sum payment in lieu of such royalty and other payments, and the conversion can only be exercised by Philips upon the acceptance of the exercise by the Company at its sole discretion. The number of 5,347,287 shares that can still be issued assumes that all outstanding warrants (entailing the issue of up to 2,370,601 new shares) have been exercised, it being understood that the actual number of shares issuable depends on a number of factors.

Bron:https://globenewswire.com/news-release/2017/12/22/1269826/0/en/Biocartis-Group-NV-Disclosure-of-outstanding-voting-securities.html

Waarom maakt Biocartis dit wel bekend en MDX niet?

quote:

Poelifinario schreef op 7 juni 2018 15:05:

Biocartis is ook een spin off van Philips.

Philips heeft het volgende recht op biocartisaandelen:

[1] The conversion option agreement allows Philips to convert certain royalty and other payments due to it up to a maximum of 10% of the then outstanding capital of the Company on a fully diluted post-money basis, but only if the Company has not yet made a lump sum payment in lieu of such royalty and other payments, and the conversion can only be exercised by Philips upon the acceptance of the exercise by the Company at its sole discretion. The number of 5,347,287 shares that can still be issued assumes that all outstanding warrants (entailing the issue of up to 2,370,601 new shares) have been exercised, it being understood that the actual number of shares issuable depends on a number of factors.

Bron:https://globenewswire.com/news-release/2017/12/22/1269826/0/en/Biocartis-Group-NV-Disclosure-of-outstanding-voting-securities.html

Waarom maakt Biocartis dit wel bekend en MDX niet?

quote:

Poelifinario schreef op 7 juni 2018 15:05:

Biocartis is ook een spin off van Philips.

Philips heeft het volgende recht op biocartisaandelen:

[1] The conversion option agreement allows Philips to convert certain royalty and other payments due to it up to a maximum of 10% of the then outstanding capital of the Company on a fully diluted post-money basis, but only if the Company has not yet made a lump sum payment in lieu of such royalty and other payments, and the conversion can only be exercised by Philips upon the acceptance of the exercise by the Company at its sole discretion. The number of 5,347,287 shares that can still be issued assumes that all outstanding warrants (entailing the issue of up to 2,370,601 new shares) have been exercised, it being understood that the actual number of shares issuable depends on a number of factors.

Bron:https://globenewswire.com/news-release/2017/12/22/1269826/0/en/Biocartis-Group-NV-Disclosure-of-outstanding-voting-securities.html

Waarom maakt Biocartis dit wel bekend en MDX niet?

quote:

SJURVM schreef op 7 juni 2018 16:37:

[...]

This is a legal requirement to let all shareholders know :

"..The number of 5,347,287 shares that can still be issued assumes that all outstanding warrants (entailing the issue of up to 2,370,601 new shares) have been exercis.."

It means therefore that MDXH has no such arrangement with Philips as they did not disclose anything. So it is a pure cash transaction.

Nothing to do with any Hocus Pocus as some would have it here in this forum.

quote:

De Troon Jan schreef op 7 juni 2018 21:16:

Dus we wachten geduldig af wat er in het vat zit voor MDX en Philips er zal bij beide partijen toch wel voordeel in zitten!

quote:

DWB Happy schreef op 7 juni 2018 17:04:

Poelifirnario,

Ik vermoed dat ze er niet veel betaald voor hebben, en mogelijk pas echt gaan betalen zodra de test op de markt komt.

Dit patent bestaat al vanaf 2010, in 2015 waren de onderzoeksresultaten al bekend, tussentijds hebben ze geen licenties verkocht, oftewel anderen zagen er weinig brood in.

www.ncbi.nlm.nih.gov/pubmed/26575822

2015
CONCLUSIONS:
We further characterise and add physiological relevance to PDE4D7 as a novel marker that is associated with the development and progression of prostate tumours. We propose that the assessment of PDE4D7 levels may provide a novel, independent predictor of post-surgical disease progression.

quote:

Poelifinario schreef op 7 juni 2018 16:49:

[...]
Ok. That makes sense.
Philips doesn't do charity however and MDX doesn't have loads of cash to spend on licensing. Furthermore, existing products are difficult to market.

SJURVM, do you have an idea how much MDX should have paid for this licensing agreement? What's your estimate of ConfirmMDX going to market?

quote:

ProveIT schreef op 8 juni 2018 10:48:

Nieuw promofilmpje voor Select :

kanker-actueel.nl/urinetest-selectmdx...